Evotec OAI AG Signs Chemical Library Agreement with Merck & Co., Inc.
Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a supplier of integrated high-value-added drug discovery services, announced today that it has entered into an agreement with Merck & Co., Inc. to synthesise small molecule chemical libraries. This represents a most significant collaboration for Evotec OAI. Financial terms of the agreement were not disclosed.
Under the terms of the agreement, Evotec OAI will synthesise well characterised drug-like library compounds using its proprietary high-speed combinatorial chemistry and auto-purification platforms. Merck will use these compounds in its drug research and development programs. "We believe that Evotec OAI’s proprietary technology platforms will uniquely contribute to our compound acquisition program." said Thomas N. Salzmann, Ph.D., Senior Vice President, Basic Research, Merck. “This major agreement reaffirms the value of our highly industrialised process for synthesising compound libraries,” said Mario Polywka, Chief Operating Officer of Evotec OAI.“ We are delighted to be working with Merck and contributing to their identification of high quality drug candidates through the application of our leading-edge chemistry solutions.”
Other news from the department science
![[Fe]-hydrogenase catalysis visualized using para-hydrogen-enhanced nuclear magnetic resonance spectroscopy](https://img.chemie.de/Portal/News/675fd46b9b54f_sBuG8s4sS.png?tr=w-712,h-534,cm-extract,x-0,y-16:n-xl)
These products might interest you
Milli-Q® Services / MyMilli-Q™ by Merck Life Science
Services & Support for Water Purification Systems
Quality Care, Delivered. In Person & Online
Good Weighing Practice by Mettler-Toledo
Your Concrete Weighing Quality Assurance Plan
GWP Verification service
